New Drug For Macular Degeneration Setting Sales Records

The new drug treatment for macular degeneration Eyelea is racing past all projections for its sales since its release in Nov 2011. The first six weeks were announced to have around $25,000,000.00 worth of the drug sold for injection into the eye. That is about 500 people per day receiving injections of Eyelea for the last 6 weeks.

Is This A New Wonder Eye Treatment Or Really That Much Better?

The primary advantage for patients with Eyelea is the recommended treatment cycle is every two months versus the monthly injection for Avastin or Lucentis. No one is in a rush to have a shot into the eye so   that is a very strong selling point. The true reason for the unexpected surge in sales probably has little to do with the frequency of injections or how Eyelea is seen to perform. The most likely cause is a small number of cases of Avastin infections that occurred inside eyes after treatment in the second half of 2011. Compared to the cost of Lucentis and Eyelea Avastin is dirt cheap ($50 compared to $1700 TO $1800 per injection). Avastin does not come in single vials like Eyelea and Lucentis, and there is the potential for contamination when it is transferred to unit doses. Since one company (Genetech) manufactures both Avastin & Lucentis it is not expected that Avastin will be retested for on lable use in macular degeneration and marketed as a single vial drug. 

What is The Future For Eyelea?

Eyelea is expected to take over about 10% of the market for eye injection treatment of macular degeneration in 2012. As the shadow falls off of Avastin, I expect it to return to popularity due to the cost and higher oversight over repackaging. Genetech is working on a new device to allow delivery into a port without frequent injections, but that appears a way off in the future. Topical eye drops for macular degeneration are expected to enter the market within the next year. Eyelea probably won’t exceed expectations anywhere near the initial release results, but it should do well. Don’t feel like you need to rush out and change the type of treatment you are currently receiving. Eyelea probably won’t treat macular degeneration any better than existing drugs. On the other hand, if the thought of frequent shots in the eye are keeping you from seeking treatment ask about Eyelea, it just might save your sight.


How Long Can You Use Eye Drops?

To Use or Not To Use (Opened Eye Medications)

Can you keep using those old eye drops and when should you throw them away? It is not the easiest question to answer but there are some guidelines.

Eye drops come in single use containers (small plastic vials with twist off caps) and in multiple dose bottles. The multidose bottles normally contain preservatives to prevent contamination. Frequently dropper tips touch the eyelids or countertops if you are not very careful. That point of contact can contaminate the bottle with bacteria. Preservatives are added to help overcome any inadvertent contamination. Preservative taken over the course of years can damage some of the surface cells on the eyes tissues and contribute to dry eye syndrome and red eyes. Preservative free single use eye drops have been developed to circumvent this problem, but they come with a hefty price tag.

Refrigerators And Eye Drops-Cool Or Not!

Most prescription eye drops are OK to use for 30 days after opening if they are kept refrigerated. Most bacteria are inhibited below 40 °F and above 140 °F. (The listeria bacteria that have been in the Colorado news of late are an exception since they thrive in cooler environments). Not only does refrigeration inhibit bacterial growth but it also helps maintain the stabilty of the drops and prevent them from degrading into other compounds. One study found the glaucoma eye drop Lumigan was much more stable than the well known xalatan drop at room temperatures. For people with glaucoma that spend frequent time traveling, eye doctors may prescribe an eyedrop like Lumigan when refrigeration is unlikely to be available. For about every 20 &deg:F rise in temperature drugs double in their instability. One thing to keep in mind is that refrigeration does not stop bacterial growth, it only slow it down. Prescription eye drops can become contaminated from bacteria inside of foods and refrigerators so it may not be the best choice for drops that are used only on a short term basis- and you should keep that thing clean anyway!

Who Knows What Really Lurks In Older Eye Medications-The Government And They Are Only Guessing!

Most prescription eye drops have a range of concentrations that are effective in killing bacteria. The potency of antibiotics is usually based on complex calculations that may not be accurate. A few drugs like tetracycline actually degrade to products that increase the resistance of bacteria to treatment. Determining shelf life is no easy task so the FDA tends to err a little on the conservative side. Eye institutions like Mooresfield Hospital in the UK frequently prepare unpreserved multiuse drops for special, severe eye infections. They have tested the sterility of these drops over the years and found that non preserved drops are typically safe to use for a week when refrigerated. Most studies indicate that multiuse preserved eye drops are good for 1 month after opening when refrigerated. 

The rule of thumb is a week for non preserved multidose drops that are kept refrigerated and 30 days for preserved multidose drops that are kept refrigerated. A study of cycloporine, the same eye medicine found in restasis for dry eye treatment, also indicated 1 week when refrigerated. The formulation was slightly different, and restasis is approved as a single time use per vial. Some eye doctors allow their patients to use the same vial for 24-48 hours. 

When you have opened eye drop prescriptions it is best to discard them after 30 days. As always, you should ask your prescribing optometrist first before using any eye medications in a manner that has not been through a formal approval and testing process. And clean that refrigerator!

Macular Degeneration Stem Cell Treatment

Macular Degeneration Treated With Stem Cells 

Several years ago I received a phone call from a reporter wanting to know more about stem cell treatments for an eye condition where the optic nerve is not fully developed. A young girl from the Fort Collins area was en-route to China for treatment. At the time I was not aware of the procedure. A lot has changed in world of eyecare since then. On July 14, 2011 the first patient in the United States received a stem cell transplant for macular Degeneration. Steven Schwartz, M.D. and Robert Lanza, M.D. Performed the procedure using embryonic stem cells developed by Advanced Cell Technology, Inc.

 

This marked the beginning of a clinical trial by eye doctors that will involve 12 people. The first patients received 50,000 retinal pigment epithelial cells derived from embryonic stem cells. Stem cells are cells that have the capacity to develop into other types of cells and tissues. Stem cells can be from embryonic or adult origins. Embryonic stem cells are removed from developing embryos several days old that were initially grown for in-vitrio fertilization procedures. The embryo is normally destroyed in the process. Dr. Lanza has developed a procedure to remove a single cell and start the stem cell line without resulting in the death of the embryo.

Is Stem Cell Use For The Eyes Safe? 

Like all clinical trials, the eye doctors do not know if the procedure will be safe or effective. It is intended to treat the dry form of macular degeneration. The dry form is responsible for the majority of cases of macular degeneration and results in millions of people suffereing with vision loss and partial blindness. This study will be completed in 2013, and if it is successful further clinical trials will be required before any treatments are approved.

 

Germany and China have had programs with ophthalmosists treating macula degeneration with stem cells. The program in Germany was closed by the government over concerns about stem cell usage. The leading program in China was developed by Beike Biotech, where doctors claim to have treated thousands of cases of different types of diseases with stem cells, including age related macular degeneration. Beike physicians report they do not use embryonic stem cells, but instead rely on adult cell lines derived from umbilical cords or bone marrow.

 

In March of 2011 vision researchers at Georgetown University Medical Center were able to induce adult stem cell lines to turn into retinal pigment epithelial cells. These cells were not robustly healthy but did mimic the functions of the normal retinal pigmented epithelial cells. In the future they hope to produce vital, healthy cells for future eye doctors use in transplantation.

Eye Treatments And Stem Cell Debate 

Adult stem cell treatment have a long and somewhat successful history. Embryonic stem cell lines were not developed until 1998 so they are a relatively new kid on the block. The same group that developed this first stem cell line also transformed skin cell into cells with similar properties in 2007. (James Thomson and Shinya Yamanka). The transformation of normal cells into stem cells will someday probably end the debate over embryonic stem cell uses in treating diseases.

We do not know if the current attempts will be successful and what the possible side effects may show up over time. Transplanting cells does not currently provide a mechanism to encourage them to hook up anf function where they are needed. There are lingering concerns about stem cells (especially embryonic stem cells) developing into the wrong types of tissues or being rejected. The long term potential of stem cell therapy in “regenerative medicine” is enormous. In 2008, a 15 year old girl in Fort Collins, Colorado traveled to China for stem cell treatment of optic nerve hypoplasia. At that time her vision was described as 20/4000. One year later she received her drivers license permit. We can hope the results in treating macular degeneration will be the same.

Viibryd And Cataracts

Does Viibryd Cause Cataracts?

Can you believe everything you see on TV? Well no-but stay tuned. Some types of age related cataracts do display a higher concentration of serotonin as part of their molecular composition. The connection to prescription drugs that alter serotonin is a little more complex that it appears to be at first glance.  The new blockbuster antidepressant vilazodone hydrochloride was released in the US market in July 2011. It falls under the category of SNRI, or a serotonin norepinephrine re-uptake inhibitor. Serotonin crosses between nerve endings to relay its message to the brain. When it is released there is also an adjacent site to reabsorb it before it crosses the gap in the nerve ending. Re-uptake inhibitors interfere with this site thus increasing the amount of “feel good” serotonin to pass along the message. After the Prozac generation of drugs, modifications were designed to also boost norepinephrine and dopamine, two other substances related to mood. Effexor, Cymbalta, Pristiq, and now Viibryd are the current SNRI medications. Viibryd claims to be unique in both blocking the re-uptake of serotonin and stimulating the serotonin receptor (type 5-HT1A).

The Eye Is An Outgrowth Of The Brain

The eye is developmentally an outgrowth of neural tissue and it is no surprise that there are a number of different types of serotonin receptors found in the different layers. The iris, ciliary body, cornea, lens,retina, central retinal artery and the ciliary artery all have serotonin receptors. The ciliary body (the root of the iris) has receptor cells that both increase the eye pressure and decrease it. There is some speculation that inadequate transformation of serotonin to melatonin by the ciliary body may lead to glaucoma. The human lens synthesizes melatonin which is known to be an antioxidant. Antioxidants like melatonin can prevent the damage free radicals inflict on lens proteins.
There is at least on type of serotonin receptor in the lens but this is not a well studied area. In animal models, serotonin disrupts enzymes (ATPase) that help provide energy to the lens epithelium (surface cells). With the loss of energy needed to keep cells healthy the lens starts to develop cataracts. Activation of serotonin receptor sites in the lens epithelial layer may also provoke cataract formation.
The fluid in the front half of the eye (aqueous humor) contains serotonin, presumably produced from the ciliary body and iris of the eyes. The lens may produce some serotonin but it probably receives most of its exposure from serotonin absorbed from the aqueous humor fluid. Taking a prescription drug like Viibryd has blocks the receptors in the brain and the receptors in the eye. Prozac has been shown to cause a transitory increase in eye pressure and in pupil dilation from blocking the re-uptake of serotonin receptor sites.

Eye Doctors Find Increase In Cataracts With Antidepressant Use In Study

A study in Vancouver in 2010 found a 15% increase in cataract formation in a large population of patients taking antidepressant drugs in the SNRI and SSRI categories. drugs. Effexor and Luvox were the worst offenders. Smoking is a known cause of cataracts and was not accounted for in this study. It is by no means a definitive study or the final word ion the subject.
Now the complicated part. There are seven known types of serotonin receptors with a number of subcategories. There are different mechanisms and activities for each one of these. The effect of Viibryd and other serotinergic type drugs on each receptor type is not completely known. SNRI drugs act in scattered small areas of the brain. The action of Viibryd is not completely known. The effect on receptors in the eye is largely unknown. It is not possible to say that Viibryd has any effect on cataract development with any degree of certitude.

Worrying Won’t Help Your Mood Or Your Eyes

Returning to reality, the 2010 study found only a 15% increase in the incidence of cataracts. That does not mean the antidepressant drugs increased your likelihood of getting cataracts by 15%, it is more like a 3% increase. When you factor in smoking, for all we know Viibryd might prevent cataracts. The activity on the the multiple types of receptor cells is not fully quantified. To my knowledge there has not been a reported association between Serotonin Syndrome and the acute .onset of cataract formation. Serotonin Syndrome occurs from an overdose of serotonin and you would expect to see this if SNRI drugs did cause cataracts.I have seen patients in my Fort Collins optometry practice that have been on SSRI and SNRI prescriptions for over 20 years with no signs of associated cataracts. This category of drugs is generally not considered a risk factor for cataracts by most eye doctors. Like any prescription you need to discuss the risks and benefits with your doctor. And most importantly help a friend quit smoking – smoking does cause cataracts, glaucoma, macular degeneration, and contributes to multiple other disease that result in blindness

Contact Lenses To Treat Eye Allergies

Acuvue K The Contact Lenses For Itchy Eyes


Contact lenses are about to enter a new realm as drug delivery devices.  While a number of applications are expected, Acuvue may be the first off the block with an antihistamine releasing lens. In 2007 Vistakon,  the manufacturer of the Acuvue lens family, sponsored a clinical study of healthy patients wearing a lenses with ketotifen.  Eye doctors followed over 300 patients and evaluated for any complications over a period of 12 weeks while they wore the lenses. On June 23 2011 the final comments were added.

Acuvue K-Lens For Eye Allergies Appears to Be A Safe Contact Lens

There were two serious problems in people wearing the Acuvue K contact lenses. One patient had to be hospitalized for gastrointestinal problems and another for a nose fracture from a fall. I believe it is unlikely these were related to the contact lenses but time will tell.  Statistical analysis of the results has not been made public but it appears that every marker of eye inflammation measured was not significantly changed by the contact lenses.  Ketotifen is the same anti-allergy drug found in the over the counter drops Zaditor and Alaway.

Itchy Red Eyes Are Only The Beginning!

Eye allergies can  diminish the quality of life when they are severe and constant. All eye drops share the common problems of accurate and prolonged dosing over time. A single drop may be blinked out and/or the amount your eye receives may last for a very short duration. By adding drugs to contact lenses eye doctors should be able to assure a steady dosage over long periods.

Many eye diseases may show much higher response rates when they are delivered in contact lenses. Glaucoma, eye infections, and uveitis (inflammation inside the eye) are probably going to be treated with contact lenses in the near future.

Someday you may even be told to take two contact lenses and call in the morning!


Dark Spots On Whites of Eyes

Dark Color Spots On Eyes

"Birth Marks On Eyes"

Ocular Melanosis-Dark Spots on The

White of The Eyes

 

Dark spots that appear over the white areas of the eyes can be usually benign growths of the pigment producing cells known as melanocytes. There are three different type of benign growths:

  1. Freckles (congenital epithelial melanosis)- these are small area of brown pigment close to the iris (colored tissue on the eye).  They are present at birth.
  2. Benign melanosis-small pigmented spots similar to freckles but appearing at middle age
  3. Ocular mlenaosis

Ocular Melanosis (Technically Congenital Ocular Melanocytosis) presents a picture similar to what is seen in the left image. There are rather dramatic large areas of gray and almost blue discoloration seen on both eyes.

You Should Have An Eye Doctor Evaluate Any Dark Spots On Your Eyes On Your Child’s Eyes

The classification of pigmented spots over the white part of the eyes is somewhat confusing. The sclera is traditionally thought of as the white of the eye. Is is covered by a thin layer known as the episclera. On top of this is the outermost layer, a transparent covering  known as the conjunctiva (which becomes inflamed during attacks of conjunctivitis or pinkeye). Pigmented spots can occur in one or all of these different layers.

Melanocytes are the cells that contain melanin, the pigment that darkens the area. There can be an increase in the number of melanocytes or in the  amount of melanin. The pigmentation changes seen in this eye were present at birth and involve increase numbers of melanocytes in the episclera and possibly the sclera. While there is some disagreement most researchers beleive there is a rare increase for the risk for a melanoma developing on the eye. About 10% of people with ocular melanocytosis will also develop a secondary case of glaucoma. If a patch of pigment manifest on the skin surrounding the eyes. it is called Nevus of Ota.  When a  Routine annual eye examinations are generally the recommended care if no changes are seen.

This may also be referred to as congenital ocular melanocytosis, blue nevus of the sclera, birth marks on the eye, and freckles on the eye. It is not the same as a dis-colorization that develops after birth. This isusually noted as Primary Acquired Melanosis and is localized in the conjunctival tiusse layers.

Fortunately this type of dark spot on the eyes is not a sight threatening condition in the majority of cases



Macular Degeneration Treatment Aptamers

Macular Degeneration Treatment

Current treatment of macular degeneration involves the use of anti-vascular endothelial growth factor drugs (VEGF). Vascular endothelial growth factors are proteins that support the normal development of blood vessels before birth. They also stimulate blood vessel growth after injuries and compromised circulation problems. The growth of unwanted blood vessels in the retina of the eye creates the vision threating issues of macular degeneration. Anti-VEGF slows this progression of vision loss.

Drug Therapy For Macular Degeneration

Aptamers are molucues fabricated to bind securely to a target. Macugen (pegaptanib) was approved in 2004 for the treatment of macular degeneration and was the first aptamer used in the treatment of any human disease. It is both an anti-vascular endothelial growth factor and a aptamer. Macugen binds to the protein responsible for blood vessel proliferation in the wet form of macular degeneration and inhibits new blood vessel formation. Eye doctors have mostly switched to using Avastin and Lucentis, which typically produce a small improvement in vision. Macugen slows progression of macular degneration but has not been shown to enhance eyesight. While Avastin and Lucentis are not aptamers, a clinical study is underway to test the addition of an aptamer to Lucentis injections.

Individualized Treatment Of Macular Degeneration

Aptamers should have a bright future in the treatment of eye diseases. Their precise targeting capacity in combination with nanotechology should allow for very individualized treatment eye doctors can only imagine today.

Eye Drops To Prevent Cataracts

Eye Drops For Cataracts?

An old eye drop maybe making a new comeback. Pirenoxine, also known as Catalin in Japan, was the subject of a recent study in China. [1] The study tested the ability of Pirenoxine (PRX) to inhibit cataract formation in test tubes. The test tubes contained crystallins, a protein found in the lens inside the human eye.  PRX appears to act by binding calcium and selenite ions. Both of these ions have been shown to contribute to cataract formation in the cortex (inner layer of the lens) when they are elevated. They act to increase the breakdown of the crystallins protein structure. By binding these ions the rate of of cataract formation in the test tubes was decreased by 38%.

Cataract Prevention Eye Drops In Use Since 1958

These eye drops have been used by eye doctors in Japan since 1958. A study in 2006 questioned why Japanese eye doctors are prescribing Catlin since there was no significant supporting evidence.[2] It has been thought to be a placebo type of treatment that has been widely adopted. Numerous companies have manufactured pirenoxine overseas under a variety of trade names. Both Allergan and Alcon have made versions of pirenoxine. Takeda is a large phamaceutical company in  a number of other countries. Santen, Ferron,  and Farmigea all produce a brand. Clarvisan, Clarvisor, and Baineiting are some of the different brands that can be found around the world. There is no FDA approved eye drop in the United States at this time.

Problems With Cataract Prevention Eye Drops

There are several potential problems with the PRX eye drop medications. Research has not yet shown any effectiveness for treating or preventing cataracts in the living eye. Another significant issue lies in the solution used to deliver the drops to the eyes. Thimerosal is used as a preservative in common preparations of this eye medication. Thimerosal is a derivative of mercury, and has a fairly high rate of allergic reactions. It also is mildly toxic to the cornea tissue of the eye, and may cause undesirable long term changes when used on a chronic basis.

We should see more research in the future that addresses both of the problems above. Hopefully we will have a new treatment for cataracts not too far down the line.

BACK TO POST
Inorg.Chem. 2011, 50 (1), pp 365–377

BACK TO POST
Sekimoto M, Imanaka Y, Kitano N, et al. Why are physicians not persuaded by scientific evidence? A grounded theory interview study. BMC Health Serv Res 2006 Jul 27; 6:92

Eye Diseases And Genetics Under Investigation

Eye Diseases With Genetic Links Number Over 500

In 2006 the  National Ophthalmic Disease Genotyping Network (eyeGENE®) database was initially setup in conjunction with an National Eye Health initiative  to encourage the development of knowledge about testing and treatment of genetically related eye diseases. Over 500 eye disorders have been identified with genetic components and the number is growing.  While still in its infancy, the future of genomics (the study of genes) has a bright future in preventing and treating eye diseases.

Eye Problems With Genetic Component Under Investigation

Aniridia and other developmental eye anomalies: PAX6, WT1, DCDC1, ELP4
Axenfeld – Rieger Syndrome: PITX2, FOXC1
Best Disease VMD2Bietti’s Crystalline Corneo-Retinal Dystrophy: CYP4V2
Choroideremia: CHM
Chronic Progressive External Ophthalmoplegia (CPEO)/Kearns-Sayre Syndrome (KSS): Mitochondrial gene panel
Cone Rod Dystrophy: ABCA4, RPGR, CRX
Congenital Cranial Dysinnervation Diseases: (CCDD) KIF21A, CHN, SALL4, TUBB3
Congenital Stationary Night Blindness:  RHO, PDE6B
Corneal Dystrophy: TGFBI, KRT3, KRT12
Doyne Honeycomb Dystrophy: EFEMP1
Familial Exudative Vitreal Retinopathy: FZD4, LRP5, NDP
Glaucoma: CYP1B1, OPTN, MYOC
Hermansky-Pudlak Syndrome: HPS1, HPS3
Infantile Neuroaxonal Dystrophy: (INAD) PLA2G6
Juvenile X-linked Retinoschisis: RS1 (XLRS1)
Leber Hereditary Optic Neuropathy (LHON): ND4, ND1, ND6
Lowe Syndrome: OCRL
Microphthalmia and Anophthalmia: SIX6, SOX2, OTX2, VSX2
Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes: (MELAS) Mitochondrial gene panel
Myoclonis Epilepsy associated with Ragged Red Fibers (MERRF): Mitochondrial gene panel
Neuropathy, Ataxia, and Retinitis Pigmentosa (NARP): Mitochondrial gene panel
Optic Atrophy Type 1: OPA1
Pantothenate Kinase-associated Neuropathy (PKAN): PANK2
Pattern Dystrophy: RDS
Retinitis Pigmentosa (RP) and Retinal Degenerations: ABCA4, RHO, RDS, IMPDH1, PRPF31, PRPF3, RP1, PRPF8, NR2E3, TOPORS, RPGR, RP2, CRB1, C1QTNF5/ CTRP5, PDE6A, PDE6B, RPE65, CA4, USH2A, EYS, KLHL7
Retinoblastoma: RB1
Sorsby Fundus Dystrophy: TIMP3
Stargardt Disease: ABCA4, ELOVL4
X-linked Ocular Albinism:  GPR143 (OA1

The Future Of The Human Genome And Eye Disease Treatments

The future holds hope for many conditions that have not been amendable to treatment in the past. Someday, thinking about treating eye diseases and preventing blindness without gene therapy will be analogous to treating infections without penicillin (or today’s version of Zithromax).

Keratoconus Eye Doctors Treatments Today

Keratoconus | Eye Doctors Contact Lenses And New Options For Treatment

Kerataconus in the Human EyeKeratoconus is an eye disease that causes vision to gradually worsen over time, as the transparent corneal tissue that covers the front of the eye thins and bulges forward, forming the cone shape that keratoconus is named for.

Eye Doctors find rapid increases in nearsightedness and astigmatism are common with frequent changes in your eyeglass prescription. Scarring of the cornea can also occur in some cases resulting in significant vision loss.


Fort Collins Keratoconus Cases Probably Effect At Least 200-400 Individuals |Tell Your Eye Doctor If You Notice These Symptoms:

  • The appearance of long light streaks in your eyesight at night
  • Visual Glare and halos around lights, especially car headlights and taillights at night
  • Double Vision
  • Distorted Vision
  • Blurry Vision making it difficult to read
  • Ghost like images of white light surrounding objects you are viewing
  • Eye sensitivity to light
  • Eye Doctors Agree Keratoconus usually shows up most commonly between the teenage years of 16 up to age 30

    When this corneal eye disease manifests at earlier ages optometrists often find a more aggressive form with ongoing, frequent changes in your eyeglass or contact lens prescription. The best guess is the occurrence rate is about 1 in 2000 people.

    Optometrist And Eye Research Institutes Know Surprisingly Little About Keratoconus But Knowledge Is Starting To Grow

    It is hard for eye doctors to pin down the exact rate of this eye disease because it can be very mild and remain undiagnosed, especially when it burns out early (form fruste), or stops progressing after several years. Corneal Keratoconus creates irregular astigmatism, causing curvatures on the cornea tissue that are not nice smooth curves. Instead the eye curvature resembles the surface of a potato with dips and valleys on a very irregular shape. This type of shape makes it very difficult for your optometrist to provide a prescription for eyeglasses that results in clear vision. The lenses would have to be made in very strange shapes to result in clear vision. Even lenses that have been designed in this manner are rendered ineffective the moment your eyes look off the center of the lens. Irregular astigmatism also occurs without keratoconus, but it does not tend to progress and result in the characteristic steepening of the cornea resembling a cone shaped area. Usually keratoconus presents in one eye and over time well over half of the eye patients will have both eyes involved.

    In the past, much speculation centered around eye rubbing and ocular allergies. Some eye physicians have speculated that Keratoconus is triggered by eye rubbing that starts an inflammatory cascade in the cornea. Frequent eye rubbing also could cause mechanical tissue breakdown in areas of the cornea that are already compromised. Research by eye doctors has shown between 6-8% of patients with keratoconus have a family history, indicating there can be strong genetic components in a small percentage of families. Over 90% of the time if you have Keratoconus it is unlikly to be passed on to your children. Several areas of chromosomes have been identified as potential genetic markers and are being investigated further.

    Also, certain eye diseases such as retinitis pigmentosa, retinopathy of prematurely (damage to the retina tissue in the back of the eye from premature birth), Leber’s congenital amaurosis (a degenerative disease of the optic nerve), and vernal keratoconjunctivitis (a type of allergic eye disease) appear to occur more frequently in conjunction  with Keratonus.

    Some disease of the body also have a degree of co-occurrence with Kerataconus- Ehlers-Danlos syndrome, Down syndrome, osteogenesis imperfecta, pseuodoxanthoma elasticum), mitral valve prolapse in the heart, Laurence-Moon-Biedl syndrome, Rieger’s syndrome and neurofibromatosis. Several of these diseases interfere with normal collagen development and may precipitate kerataconus by disrupting collagen development in the cornea.

    The changes to the cornea from Kerataconus are mostly unknown. The cornea consists of 5 layers and is about 1/2 mm thick (550 microns or about the width of 5 human hairs). The epithelium layer is the surface layers of cells. Underneath the eyes epithelium layers is a thin basement membrane sitting on the anterior limiting membrane, also know as bowman’s membrane. The bulk of the corneal thickness is in the stromal layer, where the collagen protein fibers run across the cornea, adding the tensile strength. Tensile strength is the degree a material can be stressed and still return to it’s original state and shape. Collagen is the memory material of the cornea. The structure of collagen changes in the center area of the cornea with shorter fibers, that cross more, run at different angles, run though each other, form connections to Bowmans membrane, and also form connections originating from Bowman’s membrane. It has been suggested from research by Jan P.G. Bergmanson, OD, PhD, PhD h.c, DSc, & Jessica H. Mathew, OD that this alteration in structure near the central cornea may help explain the nature of Keratoconus in the future, With shorter fibers running in differing directions with various connections the central cornea would seem to be more prone to breakdown of the normal collagen structure. Optometrists have found the bulging cone area characteristic of Keratoconus cones usually form close to the central cornea, slightly inferior, which seems to substantiate the altered central corneal tissues may play a part in the eye condition. Early changes may occur in the surface epithelial cells disrupting the basement membrane. When keratoconus begins, whatever the cause may be, protein damaging enzymes called proteases increase and start damaging the epithelial basement membrane. This is the membrane formed underneath the lowest level of epithelial cells. Subsequent breaks in the corneal anterior limiting membrane occur and the cornea starts to thin centrally, probably due to the susceptibility of the different surface anatomy of the collagen fibers under lying Bowman’s membrane. As these breaks occur the surface epithelial cells can contact the stromal level of the cornea where most of the structural framework of this eye tissue is located. Small proteins called cytokines are released and alter the fluids around the cells, leading to scarring of the cornea.  Stromal fibers may move through the anterior limiting membrane. Whatever the cause, a disruption of the normal collagen structure causes the memory shape to lose its capacity and irregular shaped corneas to subsequently develop. There are indications of changes in the different enzymes that degrade proteins and induce changes in the collagen and the spaces surrounding the cells in the cornea. Cathepsins are one type of protein that increase as kerataconus starts to occur. These could lead to destruction of the so called extra cellular matrix, the substances surrounding the cells and lead to degenerative effects in the cornea.
    They may also indirectly cause a reduction in the antioxidants and increase oxidative damage to the cornea, another theory that has been proposed. Matrix metalloproteinase-2 is also activated and changes the extra cellular matrix surrounding the corneal cells. Keratocytes are numerous cells in the cornea that produce the collagen for the fibers and the extracellular matrix components, turning mostly dormant by birth. In Kerataconus they have been observed to have increased apoptosis (increased programmed cellular death). There is a reduction in the number of collagen fiber and they also reduce in diameter. While there is little indication of dry eye causing Keratoconus, at our Dry Eye Institute of Northern Colorado, we do seem to see a possible correlation. Dry Eye Syndrome increases inflammatory compounds in the tear film that do cause cellular damage in the epithelium layers. It is possible this could start the cycle of damage that  helps initiate damage to the eye that optometry eye exams have found over the years. While this has not been suggested yet, there is a reasonably high level of floppy eyelid syndrome associated with obstructive sleep apnea and Keratoconus. Eye researchers Cintia S De Paiva, Lindsey D Harris, and Stephen C Pflugfelder have demonstrated it is possible that eyes exposed at night by staying partially open can create Keratoconus like change in the cornea. Most likely, keratoconus will be found to be several different disease processes and also multifactoral. Multifactoral eye diseases have multiple factors that combine to create the eye condition. For instance, the different collagen structure in the central cornea makes the eye susceptible, changes in enzymes may alter the tissues and start causing minor breakdowns in the epithelial surface cells, enzyme changes may lead to increased oxidative stress further weakening the eye tissue, and constant rubbing of the eyes may push the eyes over the edge by inducing mechanical damage to the eye tissues that could only occur with a compromised cornea. A genetic alteration of the cornea could make the cornea of the eye more susceptible to the entire chain of events.

    Your eye doctor will initially treat Kerataconus with contact lenses. Treatment of Kerataconus usually begins with a rigid gas permeable contact lens when vision can no longer be maintained clearly with spectacle lenses. Sometimes, a gas permeable lens will be fit over the top of a soft contact lens in a piggyback contact lens fitting, with a soft contact lens and a rigid gas permeable contact lens on top of it. While used years ago, piggyback contact lens fittings fell out of favor due to the complications from reduced oxygen flow with older soft contact lenses. With the new super oxygen permeable silicone hydrogel soft contact lenses, it is enjoying a small resurgence. It is primarily used to increase eye comfort for the keratoconic eye patient. There are also combination contact lenses available today, such as the SynergEyes contact lens that is a rigid contact lens with a soft skirt attached surrounding the lens. The primary issue with Kerataconic contact lens fittings is matching the steeply curved cone with the surrounding flatter eye tissue, while dealing with the irregularities of curvature that are present. While custom mapping technology is highly touted as the way to achieve the required fit, the truth is observation of contact lenses on a keratoconic eye by an optometrist and adjustments based on how dyes accumulate under the contact lenses is still the most accurate method to achieve an excellent final fit. Due to the drastic changes in curvature the contact lenses require multiple different curves as you move toward the edge of the lens. While many different lenses have been developed with special names as the ultimate Keratoconus contact lens, they are all variations on the basic concept of a steep contact lens center and a gradient of changing curvatures to the edge. Rigid contact lenses work because the light bending capacity of the tears is very close to the light bending capacity of the cornea. The tears fill in between the irregular eye surface and the smooth surface on the back of the lens. This essentially removes the irregular astigmatism and nearsightedness by utilizing the back contact lens surface as a new regular surface where light is altered, and often restores the corrected eyesight close to 20/20. Eye glasses may only achieve 20/40 vision or much worse because the irregular surface remains. Occasionally Scleral rigid gas permeable lenses are used. These are gas permeable lenses larger than normal that extend out onto the white part of the eye. All contact lenses today are gas permeable, or designed to let air pass through to keep the cornea healthy. Soft contact lenses are usually not referred to as gas permeable because of historical changes. Hard lenses were the first contact lenses and they were made of a material that passed no oxygen through the lens. When changes were made to the polymers used to make hard contact lenses that allowed them to breathe or pass needed air to the underlying cornea, they were renamed rigid gas permeable contact lenses. Rigid because they are still a hard material with only 1-2% water, and gas permeable because unlike the older hard contact lenses they now transmitted air to the eyes. Soon they became called by the acronym of RGP’s to save a few words (even prior to the texting era). With time they also came to be referred to as gas perms, in spite of the fact that all soft contact lenses are also gas permeable. Soft contact lenses are never rigid however, as they normally are composed of about 50% water. This softness comes at the price of increased flexibility and they drape across the eye, imitating the irregularities of a Keratoconic cornea and do not correct the vision back to optimum levels. Once your eye doctor has achieved an excellent fit and optimized your contact lens prescription, there may be frequent changes in your contact lens prescription as the Keratoconus goes through progressive changes.

    Your Eye Doctor May Be Able to Avoid Corneal Transplants

    While only 10-20% of eyes will undergo ongoing serious changes, they do present challenges to fitting contact lenses on eyes with Kerataconus. At some point, scarring of the cornea can start to occur and patients become intolerant to contact lenses. In years past, the only remaining option was a corneal transplant. While corneal transplants enjoy a relatively high success rate, there are still risks and problems. Recently there have been some new exciting options starting to evolve.

    Permanent Contact Lenses-Intacs

    Intacs are small rigid half rings similar to portions of a gas permeable contact lens that are implanted in the cornea. They were originally developed to reverse nearsightedness, but did not prove as effective as originally thought and were replaced by LASIK eye correction procedures. A few years ago they found a new use in stabilizing Kerataconus. They are not a cure for Kerataconus, but can restore some more regularity and allow some patients to continue contact lens wear while avoiding a corneal transplant. They also appear to have some effect in decreasing the rate of change in Kerataconus. While they are promoted as being completely removable and reversible if patients have problems, this is not entirely true. About 10-15% of Intacs cause some complications and issues that cannot be resolved if they are removed. Still, it is often a better option than jumping straight to a corneal transplant.

    Kerataconus Corneal collagen cross-linking therapy

    Corneal collagen cross-linking therapy (CXL) is intended to stabilize the tissue by forming more bonds between the existing collagen fibers and also increasing the size of the fibers, making the cornea much firmer and less likely to continue deforming. It involves pretreatment the cornea with riboflavin (Vitamin B2) for 30 minutes then using radiation from the ultraviolet A band light spectrum (normally around 370 nanometers) to increase the cross links over about a 30 minute period. While it has been more extensively in Europe, it is starting to enter the U.S. market. The riboflavin acts to keep the UVA from completely passing through the cornea so the UV can act to create more cross links. Riboflavin also may have a photo reactive effect that further increases cross linking of the collagen bands. Questions still surround this treatment. It is not an FDA approved treatment in the United States but is undergoing clinical trials, and currently is used off label as a treatment for Keratoconus. The FDA (Food and Drug Administration) regulates drugs and medical devices but not eye doctors. Any procedure that uses drugs or medical devices can be performed by an eye doctor if you are properly informed, share in the decision, and it has an acceptable possibility of helping. The riboflavin still allows a significant amount of UVA to pass through the cornea. This could potentially increase future risks for cataract development. UVA with riboflavin is cytotoxic (damaging to cells) and can damage the endothelial cells that line the back of the cornea and are vital for its long term health. Corneal thickness needs to be factored in to keep this type of damage far enough away from the endothelium cells of the cornea. A minimum corneal thickness of 400 microns has been suggested but a better choice would be 450 to 500 microns. Cellular damage to the keratocytes, changes to the matrix of the cornea, and changes to the epithelium do occur in the cornea after the procedure. Normally they regenerate over the next 6 months. Riboflavin has poor penetration into the cornea so the surface layers of epithelium cells need to be removed. It is unknown if the effect of increased rigidity created by this treatment will last indefinitely, or if there are any other long term problems from increasing the cross linking and rigidity of the cornea. Some cases of persistent haze, infections, and increased eye pressure reading have been noted. The increased eye pressures may be partially due to an artifact since we know thicker (more firm) corneas read artificially high with most current glaucoma instruments. With careful consideration about the stage of Keratoconus and treatment of the eye at the appropriate stage, cross linking of collagen fibers in the cornea appears to be a great addition to eye doctors armetarium in treating keratoconus. While it may improve the condition mildly in many patients, it should always be considered as a stabilizing treatment and not a curative treatment.

    New treatments for Keratoconus and other eye diseases are improving at a rapid rate. If you are a family members have concerns about Keratoconus, feel free to contact Dr David Kisling in Fort Collins, Colorado at (970) 225-0959.

WP SlimStat